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Abstract
Background: Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis
(DVT) that develops in 20–40% of patients within 1–2 years after symptomatic DVT. Affected patients have chronic leg
pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated
mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that
often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the
development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic
compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and
conflicting.
Methods/Design: The SOX Trial is a randomized, allocation concealed, double-blind multicenter clinical trial. The
objective of the study is to evaluate ECS to prevent PTS. A total of 800 patients with proximal DVT will be randomized
to one of 2 treatment groups: ECS or placebo (inactive) stockings worn on the DVT-affected leg daily for 2 years. The
primary outcome is the incidence of PTS during follow-up. Secondary outcomes are severity of PTS, venous
thromboembolism (VTE) recurrence, death from VTE, quality of life and cost-effectiveness. Outcomes will be evaluated
during 6 clinic visits and 2 telephone follow ups. At baseline, 1 and 6 months, blood samples will be obtained to evaluate
the role of inflammatory mediators and genetic markers of thrombophilia in the development of PTS (Bio-SOX substudy).
Discussion: The SOX Trial will be the largest study and the first with a placebo control to evaluate the effectiveness of
ECS to prevent PTS. It is designed to provide definitive data on the effects of ECS on the occurrence and severity of PTS,
as well as DVT recurrence, cost-effectiveness and quality of life. This study will also prospectively evaluate the predictive
role of biomarkers that are reflective of putative underlying pathophysiological mechanisms in the development of clinical
PTS. As such, our results will impact directly on the care of patients with DVT.
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Background
The post thrombotic syndrome
The post thrombotic syndrome (PTS) (sometimes called
'post-phlebitic syndrome') is a chronic condition that
develops in 20–40% of patients within 1–2 years after
symptomatic deep venous thrombosis (DVT). A severe
form, which can include venous ulcers, affects 1/4 to 1/3
of patients with PTS [1]. In contrast to research gains in
the areas of diagnosis, prevention and treatment of acute
venous thromboembolism (VTE), PTS has been under-
studied and as a result, treatment options are limited.
Patients with PTS experience pain, heaviness, swelling, or
other symptoms in the affected limb, which are typically
aggravated by standing or walking and improve with rest
and recumbency. Edema, venous ectasia, hyperpigmenta-
tion, eczema, and varicose collateral veins may be appar-
ent. In severe cases, ulceration can occur [2].
Since PTS is a direct consequence of DVT, its prevalence is
influenced by the incidence of DVT. Despite advances in
VTE prevention and treatment, the annual incidence of
VTE has not decreased over time, and remains at 1.0–1.6
per 1000 persons per year, with a per-person lifetime inci-
dence of 2–5% [3,4]. Because of its prevalence and chro-
nicity, PTS is expensive, both in terms of direct medical
costs and indirect costs such as loss of productivity and
thus it is burdensome to patients and society [5].
Risk factors for the development of PTS
While hereditary and acquired risk factors that predispose
to the development of VTE are widely known [6], factors
that influence the development of PTS after DVT have not
been well elucidated. The only clearly identified clinical
risk factor for PTS is recurrent, ipsilateral DVT [7,8]. The
site (proximal vs. distal), size and occlusiveness of the ini-
tial DVT and the intensity (i.e. target INR) of long term
anticoagulation for DVT do not appear to reliably predict
PTS [1,7-10]. It is not clear why some patients develop PTS
while others recover from their DVT. As a result, physi-
cians are unable to provide their DVT patients with relia-
ble, individualized prognostic information.
Potential role of inflammation, d-Dimer and 
thrombophilia in the post-thrombotic syndrome
While the pathophysiology of PTS is incompletely under-
stood, it is likely that the acute thrombus itself, associated
mediators of inflammation, and the process of vein reca-
nalization in the weeks following DVT induce damage to
venous valves, leading to valvular incompetence (reflux).
Valvular incompetence and/or persistent venous obstruc-
tion by thrombus cause venous hypertension, which pro-
motes capillary leakage of plasma proteins, erythrocytes
and leukocytes and the development of venous ectasia
and varicosities. The result is edema, tissue hypoxia, and
ultimately, in some cases, skin ulceration [11-14].
Inflammation and thrombosis are closely interrelated
[15-17]. It has been appreciated over the last few years
that arterial atherothrombosis is, at least in part, an
inflammatory disease, and that elevations in markers of
inflammation, such as C-reactive protein (CRP), increase
the risk of future clinical cardiovascular events [18]. Clin-
ically, patients with DVT exhibit cardinal signs of inflam-
mation such as redness, warmth, swelling, pain and fever.
Several clinical studies have examined the association
between levels of inflammatory markers and venous
thrombosis, and found that a two- to six-fold increase in
the risk of DVT associated with elevations in plasma levels
of CRP, interleukin (IL)-6, IL-8, monocyte chemotactic
protein (MCP)-1 or tumor necrosis factor (TNF)-alpha
[19]. A recent paper showed that CRP is elevated in
patients with acute DVT (median 37.5 mg/L) compared
with controls (5.0 pg/L), and that levels decline during the
first 5 days of DVT treatment. Similar trends were noted
for IL-6 [20], leading the authors to conclude that the
thrombotic process produces a systemic inflammatory
response and to speculate whether the observed decrease
in levels was partly caused by treatment with heparin,
which is known to have anti-inflammatory properties dis-
tinct from its anticoagulant properties [21]. Whether lev-
els of markers of inflammation are predictive of PTS has
not previously been examined.
D-dimer is a degradation product of cross-linked fibrin
that reflects fibrinolysis and is an indirect marker of coag-
ulation activation. Recent work performed by our group
and by others suggests that D-dimer levels appear to be a
significant predictor of first VTE [22] and of recurrent VTE
[23-28], whether measured during or after anticoagula-
tion. Independent of VTE recurrence, persistent coagula-
tion activation, as reflected by elevated D-dimer levels,
may also predict a higher risk of developing PTS after DVT
[29].
Thrombophilia refers to an inherited or acquired predis-
position to VTE. Over 10% of the general population is
affected by one or more identifiable inherited throm-
bophilias which have been shown to underlie at least 1/3
of cases of VTE [30]. The most common inherited throm-
bophilias are the single nucleotide polymorphisms Factor
V Leiden, which renders coagulation factor V resistant to
the anticoagulant effects of activated protein C [31], and
Prothrombin G20210A, which leads to elevated plasma
prothrombin levels [32,33]. Recent studies have also
established that elevation of Factor VIII level is an inher-
ited risk factor both for first and for recurrent VTE [34-36],
independent of age, sex, Factor V Leiden, ProthrombinBMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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G20210A or markers of acute phase activation such as
CRP [35,37,38].
While results of a few studies to date suggest that throm-
bophilia does not increase the risk of developing PTS
[7,8,10], not all thrombophilias have been examined and
interactions among disorders have not been studied. Fur-
ther investigation of the potential link between throm-
bophilia and PTS is warranted.
Management of PTS
PTS could be averted by primary prevention of the initial
DVT with the judicious use of thromboprophylaxis [39],
and by preventing recurrent ipsilateral DVT by prescribing
adequate anticoagulation for the initial DVT [40]. How-
ever, at least 1/2 of all cases of DVT occur unpredictably,
hence are not preventable [41,42]. There is no definitive
evidence that using thrombolysis to treat DVT reduces the
incidence of PTS [43]. The treatment of established PTS is
limited and frustrating for patients. Severe PTS can be
managed with long-term use of an intermittent compres-
sion extremity pump [44,45]. Management of venous
ulcers is labor intensive and protracted, and involves com-
pression therapy, leg elevation, topical dressings, and
sometimes surgery [2,46]. Ulcers are often recalcitrant to
treatment, and tend to recur [47].
A significant reduction in the overall burden of PTS is
unlikely to be achieved by attempts to prevent the initial
DVT or by treatment of established PTS. Rather, strategies
that focus on preventing the development of PTS in
patients with DVT are more likely to be effective and cost-
effective in reducing the patient and societal impact of
PTS.
Elastic compression stockings for the prevention of PTS
Graduated elastic compression stockings (ECS) work by
providing graded compression to the leg that is highest at
the ankle, which assists the calf muscle pump, reduces
venous hypertension and valvular reflux, and conse-
quently reduces edema, improves tissue microcirculation,
and prevents skin breakdown [48,49]. Both knee-length
and thigh-length stockings appear to have equal physio-
logical effects, but knee-length ECS are easier to apply and
are more comfortable [50]. The effectiveness of daily use
of ECS to prevent PTS is supported by two studies [8,51]
but challenged by another [52]. All three studies have lim-
itations that could affect their validity and generalizabil-
ity. The first trial, Brandjes' study of 194 patients with
symptomatic proximal DVT, provides evidence support-
ing the effectiveness of ECS. Patients were randomized to
daily use of custom-made, knee-length ECS applied
within 2–3 weeks of diagnosis for at least 2 years (class II
compression, i.e. 30–40 mm Hg pressure at the ankle), or
no stocking. Use of ECS resulted in a 50% reduction in the
incidence of PTS, diagnosed using a modification of Villa-
lta's clinical PTS scale [53], or an absolute decrease from
47% to 20% of mild/moderate PTS and from 23% to 11%
of severe PTS [51]. In contrast, a randomized trial con-
ducted by Ginsberg suggested that ECS were not of benefit
in preventing PTS [52]. A strength of Ginsberg's study was
the use of a control comparison group that wore sham
stockings (i.e. stockings that were 1–2 sizes too big to be
effective). However, because of the small number of
patients with PTS, benefit or harm of up to 30% could not
be definitively excluded. Recently, Prandoni published
the results of a trial performed at a single center in Italy to
evaluate the effectiveness of ECS to prevent PTS [8].
Among 180 patients with proximal DVT, those rand-
omized to wear daily ECS had a 50% reduction in the rate
of PTS after a 2 year period, compared with controls. This
study, like Brandjes', lacked a placebo control, an impor-
tant limitation due to the subjective nature of many of the
components of the standardized scale that was used to
diagnose PTS [54]. As the Prandoni study was the first, sin-
gle positive study of "off-the-rack" elastic compression
stockings, it requires replication. Also, as the study was
conducted entirely at a single center in Italy, further eval-
uation of the generalizability of this data to North Ameri-
can clinical practice in a multi-center study is needed.
In light of the above, we believe that a large scale, rand-
omized placebo-controlled trial of ECS to prevent PTS is
needed to provide definitive evidence of effectiveness, or
lack of effectiveness, of ECS. This will allow physicians to
make informed, evidence-based decisions regarding their
use in DVT patients. Furthermore, such a trial will permit
prospective evaluation of the predictive role of markers of
inflammation, d-Dimer and thrombophilia in PTS.
Methods/Design
The SOX Trial is a Canadian, multicenter, randomized
double-blind controlled trial in patients with a first epi-
sode of proximal DVT.
Aims of the study
The primary aim of the study is to evaluate whether grad-
uated elastic compression stockings compared to inactive
(placebo) stockings, worn daily for 2 years after DVT is
diagnosed, decrease the incidence of PTS.
Secondary aims are 1) to evaluate whether active com-
pared with inactive stockings reduce the severity of PTS, 2)
to compare mean quality of life (QoL) scores during fol-
low-up in the active intervention vs. control groups, 3) to
describe the rates of recurrent DVT, death from VTE,
venous ulcers, and major bleeding during the 2-year fol-
low-up in the active intervention vs. control groups, 4) to
evaluate the cost-effectiveness of ECS for the prevention of
PTS, and 5) to determine whether markers of inflamma-BMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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tion, D-dimer and thrombophilia influence the develop-
ment and severity of PTS (Bio-SOX biomarker substudy).
Trial design and description of the intervention
Original trial design
The study was initially designed as a factorial design ran-
domized clinical trial whose primary aims were to deter-
mine whether (1) elastic compression stockings used for
2 years compared to inactive (placebo) stockings, and (2)
celecoxib, a COX-II inhibitor, used for 30 days compared
to placebo, were effective in preventing PTS in patients
with symptomatic proximal DVT. The rationale for the use
of a COX-II inhibitor was to assess whether an anti-
inflammatory drug used acutely could limit the extent of
venous valvular damage and reduce the frequency of sub-
sequent PTS. However, in December 2004, The National
Institutes of Health announced suspension of the use of
celecoxib for all participants in a large colorectal cancer
prevention clinical trial conducted by the National Cancer
Institute, because analysis by an independent Data Safety
and Monitoring Board (DSMB) showed a 2.5-fold
increased risk of major fatal and non-fatal cardiovascular
events for participants taking the drug compared to those
on a placebo. As a result of this announcement, the SOX
Trial Steering Committee decided on December 21, 2004
to discontinue the Celecoxib intervention of the SOX Trial
[55]. This decision was made after independent meetings
of the Steering Committee and the SOX Trial DSMB and
was based on patient safety and also on study feasibility.
The SOX Trial thus resumed in February 2005 as a parallel
group randomized trial, i.e. without the celecoxib/pla-
cebo intervention.
Current trial design
The study is a randomized, allocation concealed, double-
blind multicenter clinical trial with an intervention alloca-
tion ratio of 1:1 (figure 1 summarizes the study design).
Once a patient is deemed eligible and consents to the
study, the research nurse at each site logs onto a web-
based interface which allocates the patient to one of 2
treatment groups: active stockings or inactive (placebo)
stockings. Treatment group is assigned randomly using
permuted blocks of randomly varying sizes at each study
site to maintain close balance of the numbers in each
treatment group, at any time during the trial, and to
ensure allocation concealment. The active stockings inter-
vention consists of knee-length, 30–40 mm Hg (Class II),
graduated ECS worn on the DVT-affected leg daily,
applied upon waking and removed upon retiring, begin-
ning as early as possible within 14 days after DVT diagno-
sis and continued for 2 years. The inactive stockings
intervention (the control intervention) consists of knee-
length, inactive stocking (5 mm Hg compression at ankle;
similar to store bought trouser sock), identical in appear-
ance to the active stockings, worn on the DVT-affected leg
daily, applied upon waking and removed upon retiring,
beginning as early as possible within 14 days weeks after
DVT diagnosis, and continued for 2 years. Active and inac-
tive stockings are manufactured by SIGVARIS Corp.
Patient eligibility criteria
Patients presenting with a first, symptomatic, objectively
confirmed proximal DVT diagnosed within the last 10
days (with or without concurrent distal DVT or pulmo-
nary embolism), who have no contraindications to stand-
ard anticoagulant therapy and who provide informed
consent are eligible for the study.
Patients are excluded if they 1) have a contraindication to
compression stockings e.g. previously documented mod-
erate to severe peripheral arterial disease of the lower
extremities, absence of palpable pedal pulses or arterial
compromise due to massive venous obstruction; 2) have
a limited lifespan (estimated < 6 months); 3) have geo-
graphic inaccessibility preventing their return for follow-
up visits; 4) demonstrate inability to apply stockings daily
(e.g. severe arthritis, arm paralysis, and unavailability of a
caregiver to apply stockings daily); or 5) were prescribed
lytic therapy to treat their acute DVT.
Study procedures
Once the patient is recruited and randomized via the SOX
Trial's web-based interface, the computer generates a
unique treatment code for each patient, according to treat-
ment group and center. The study nurse faxes the patient's
leg measurements to the stocking supplier, who then
ships the assigned pair of ECS to the patient (i.e. correct
size, according to patient's measurements; active or inac-
tive stocking, according to patient's treatment code). ECS
are pre-packaged by the manufacturer in a plain box,
labeled with the unique stocking code (i.e. patient and
health personnel blinded). The same procedure is used to
replace the patient's ECS every 6 months during the trial.
Several strategies are used to protect against bias, includ-
ing: randomization with allocation concealment, enroll-
ing consecutive patients, blinding subjects to treatment
assignment, blinding investigators, study nurses and out-
come assessors (e.g. vascular technicians, radiologists) to
treatment assignment, strict inclusion and exclusion crite-
ria, and use of validated measures to diagnose PTS, recur-
rent VTE and to measure QoL. To prevent unblinding of
study nurses, patients are instructed not to wear ECS on
the day of their study visits. While it is possible that
patients may be able to distinguish active from inactive
ECS, this is minimized by (1) using inactive ECS, devel-
oped by the manufacturer, that appear identical to active
ECS, and (2) recruiting patients with a first DVT, i.e. likely
to be "ECS-naïve". In addition to such pre-trial design fea-
tures, we will assess the blinding procedures by askingBMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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Study architecture-Flow diagram: The SOX Trial Figure 1
Study architecture-Flow diagram: The SOX Trial.
Consecutive patients with first proximal DVT assessed for eligibility
Excluded if 
3. Limited lifespan
4. Geographic inaccessibility
5. Treatment of acute DVT 
with thrombolytic agents 
1. Contraindication to 
compression stockings 
2. Inability to apply
stockings daily
Eligible and consenting patients 
R
Active Stocking 
for 2 years 
Inactive Stocking
for 2 years 
Primary outcome
PTS incidence
Secondary Outcomes
PTS severity, reflux 
VTE recurrence, VTE death
Major Bleeding 
Markers of inflammation, thrombophilia, d-dimer
QOL
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patients, investigators and research nurses at the end of
the trial (i.e. at 2 years or at time of study termination) if
they were aware of the treatment assignment.
Study patients are followed for 2 years after enrollment.
The procedures at each visit are shown in Table 1. At any
time during the study, if a patient has symptoms or signs
suggestive of recurrent VTE, he contacts the study team for
medical assessment, at which time recurrent VTE will be
ruled in or ruled out. Similarly, if an adverse event occurs,
the patient contacts the study team for evaluation. If a
patient withdraws from the study, a Study Termination
form is completed to account for withdrawal, which will
document the reason(s) for withdrawal. If a patient dies,
a Death Form is completed which documents the cause(s)
of death, further classified as VTE likely or unlikely.
Throughout study follow-up, co-interventions are
recorded (e.g. diuretics, analgesics, exercise). While not
encouraged, any temporary use of elastic bandages/wraps
or active stockings during the acute phase of DVT is sys-
tematically tracked.
Primary and secondary outcome measures
The primary outcome measure is the incidence of PTS dur-
ing 2 year follow up. PTS will be diagnosed at the 6 month
visit or later if the patient reports pain and swelling of ≥ 1
month's duration that is typical in character (worse at the
end of the day or with prolonged sitting or standing, and
better after a night's rest and leg elevation), and that is
present ≥ 6 months after the acute DVT [52]. Patients diag-
nosed with PTS will be considered to have reached the
study endpoint. Severity of PTS will be graded according
to the Villalta scale [53], a clinical post-thrombotic syn-
drome measure that rates the severity of five patient-rated
symptoms and six clinician-rated clinical signs [53]. A Vil-
lalta score of 5–9 represents mild post-thrombotic syn-
drome; 10–14, moderate post-thrombotic syndrome; and
> 15 or presence of a venous ulcer, severe post-thrombotic
syndrome [53].
Secondary outcomes measures include:
￿ Reflux: Reflux will be assessed and quantified in a stand-
ardized fashion by venous ultrasound [52,56].
￿ Recurrent VTE: Objective tests and validated algorithms
will be used to diagnose recurrent DVT and PE, as
described previously [57-59], and all events and deaths
will be independently and blindly adjudicated. Death
from VTE will be assessed as 'likely' or 'unlikely' after
review of the death certificate, patient chart, autopsy
report (where available) and by contacting the treating
physician.
￿ Bleeding: Clinically suspected bleeding events will be
documented by recording the clinical event and results of
any objective diagnostic testing performed. Bleeding will
be defined as major if it is clinically overt and associated
with a fall in hemoglobin of 20 g/L or a need for transfu-
sion of ≥ 2 units of red blood cells; if it was intracranial or
retroperitoneal; or if it warranted the permanent discon-
tinuation of anticoagulation. Less severe clinically overt
bleeding which is considered abnormal will be classified
as minor.
￿ Markers of inflammation: C-reactive protein will be
assayed using a nephelometric assay. IL-6, IL-8 and MCP-
1 will be measured using commercial ELISA kits which
include plasma controls (Biosource Europe SA, Nivelles,
Belgium). At the time of blood draw for markers of
inflammation, data will be recorded on time of day, type
and duration of heparin use, concomitant medications
and medical conditions.
￿ DNA polymorphisms associated with thrombophilia:
QIAGEN kits and standard protocols will be used to
extract DNA from peripheral blood leukocytes. Samples
will be run on the ABI Prism 3100 Genetic Analyzer to
analyze Factor V Leiden, Prothrombin G20210A, PAI-1
4G/4G, TAFI T1053C, TFPI C536T, TFPI T33C and FXIII
Val34Leu.
￿ Coagulation and ELISA-based assays: Factor VIII assays
will be performed using the PTT based Diagnostica Stago
(Abbott Diagnostics Canada, Mississauga). D-dimer test-
ing will be performed with the IL-Test Latex Agglutination
method (Instrumentation Laboratory, Lexington, USA).
Lupus anticoagulant testing will be performed on an
ACL9000 (Instrumentation Laboratory, Lexington, USA).
Standard aPTTs are performed using Alexin HS (Trinity
Biotech USA, St. Louis, USA) and HemosIL APTT-SP
(Instrumentation Laboratory, Lexington, USA) as a
screening test. Abnormal results are followed by a 50:50
mix using Cryocheck Normal (Precision Biologic, Dart-
mouth, NS), followed by Platelet Neutralization Proce-
dure. Additionally, a Dilute Russell Viper Venom test is
performed using IL test LAC Screen followed by Confirm
(Instrumentation Laboratory, Lexington, MA, USA). IgG
and IgM antiphospholipid antibodies are tested usin-
gapHL-HRP ELISA Kit (Louisville APL Diagnostics,
Doraville, USA).
￿ Quality of life measures: Quality of life will be measured
using the SF-36 questionnaire for generic QOL [60,61].,
and the VEINES-QOL/Sym questionnaire for venous dis-
ease-specific quality of life, which our group developed
and validated [62,63]BMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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￿ Cost Effectiveness measures: A decision tree-based cost
effectiveness analysis will be used to assess the relative
cost-effectiveness of the active stockings in reducing the
incidence of PTS, as compared to a strategy of inactive
stockings [64,65]. Tree structure will schematically reflect
the clinical trajectory for each strategy [66]. Sensitivity
analyses will be conducted to verify the robustness of the
qualitative conclusions to variations in the data [67].
Sample size and power calculations
We hypothesized that event rates (i.e. PTS at 2 years) will
be 30% in the inactive stocking vs. 20% in the active
stocking group, i.e. a risk reduction of 33%. Our baseline
event rate and effect size for the stocking group were based
on a systematic review of available published data [68].
The total sample size required to detect this difference in
event rates with a two-tailed α of 0.05 and 80% power is
600 [69]. We increased our sample size to 800 to take into
account a projected 25% loss-to-follow up by 2 years.
For the biomarker analyses, our sample size provides >
80% power to detect ORs of 0.5 or lower, or 2.0 or higher.
Larger alternatives will be associated with increased
power. With regard to inflammatory markers, the analysis
will be largely exploratory, as this study will be among the
first to provide prospective data on levels of markers of
inflammation in patients with DVT and PTS. However,
the study design provides power of at least 80% to detect
differences on the order of 1/3 of a standard deviation or
larger between initial values of inflammatory markers in
the two allocation groups.
Statistical analysis
An intention-to-treat analytical approach will be used for
all outcomes. Descriptive statistics for baseline variables
Table 1: Details of study visits and telephone calls
Enrollment visit
• The nurse completes the baseline form (inclusion/exclusion criteria, demographic and clinical variables, results of objective tests for DVT), PTS 
scale and pain scale
• The patient self-completes the QOL form
• The nurse performs the leg measurements to size the stockings
• The nurse teaches patients how to apply (using a plastic leg model) and care for stockings (handling, washing), and reinforces the importance of 
daily use
• Study stockings are supplied to the patient (within a few days after enrollment)
• A venous blood sample is taken for markers of inflammation
2-week telephone call
• The nurse reinforces the importance of wearing stockings daily
• Bleeding/Other Adverse Event form and pain scale are completed
For the following visits, the patient does not wear study stocking to prevent unblinding of study nurse:
1-month visit
• The nurse completes the follow-up form (includes data on symptoms and signs of PTS, suspected recurrent VTE, compliance with stockings, pain 
scale)
• The patient self-completes the QOL form
• Bleeding/Other Serious Adverse Event form is completed
• A venous blood sample is taken for markers of inflammation and genetic thrombophilia
• The nurse reinforces the importance of wearing stockings daily
2-month telephone call
• Same as the 2-week telephone call
6-month visit
• The nurse completes the follow-up form
• The patient self-completes the QOL form
• Bleeding/Other Serious Adverse Event form is completed
• Leg measurements are taken, and a new pair of stockings is supplied
• A venous blood sample is taken for markers of inflammation, d-dimer and coagulation-based assays
• The nurse reinforces the importance of wearing stockings daily
1-year visit
• Same as 6-month visit except no blood sampling
• A venous ultrasound is performed to assess reflux
18-month visit
• Same as 6-month visit except no blood sampling
2-year visit
• The nurse completes the follow-up form
• The patient self-completes the QOL form
• Bleeding/Other Serious Adverse Event form is completed
• The success of blinding (patient, nurse, and investigator) is assessed (or at Study Termination if earlier than 2 years).BMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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will be calculated to describe the baseline status of the
treatment groups. For the primary outcome variable PTS,
a logistic regression analysis initially adjusted only for
center will be used to compare the incidence rates
between the active vs. inactive stockings groups. In sec-
ondary analyses, other covariates that will be adjusted for
are duration of anticoagulation with warfarin, recurrent
ipsilateral DVT during follow-up, temporary use of active
stockings, initial type and duration of heparin anticoagu-
lation, co-morbid conditions that could lead to leg symp-
toms/signs and differences in pertinent baseline variables.
The number needed to treat for benefit will be calculated.
As an adjunct to the primary analysis, a secondary explan-
atory (per-protocol) analysis will be performed as well.
Subgroup analyses by age, sex, level of compliance, dura-
tion of warfarin anticoagulation and recurrent VTE during
study follow-up are also planned.
For the secondary outcomes valvular reflux, recurrent VTE,
death from VTE, venous ulcer, major bleeding, and sever-
ity of PTS, rates in the two intervention groups will be
described, and between-group differences explored in
similar regression procedures. For differences in mean
quality of life scores between intervention groups, analy-
sis of variance incorporating treatment and center will be
used. A difference of 4–5 points between groups is consid-
ered to be clinically meaningful. Analysis of covariance
with adjustment for age, sex and comorbidity will also be
used to compare quality of life between groups. For the
biomarker variables, univariate analysis will be used to
determine the strength of association between each
biomarker variable and the occurrence of PTS. For genetic
markers, heterozygotes and homozygotes will be analyzed
together, given the rarity of homozygotes. IgG, IgM and
lupus anticoagulant results will be dichotomized as nor-
mal or abnormal. Factor VIII, D-dimer and markers of
inflammation will be analyzed both as continuous data
and as proportion of values exceeding the upper 90th per-
centile. For binary and nominal data, the appropriate chi-
square tests will be used to examine the respective crude
associations, and for continuous variables, the unpaired
2-tailed t-test. To examine adjusted associations, multiple
logistic regression analyses will be performed in which the
dependent variable is the presence of PTS. The independ-
ent variables to be tested are markers of thrombophilia,
D-dimer, and levels of CRP, IL-6, IL-8 and MCP-1. Other
variables of interest (for interaction and/or confounding)
are age, sex, ethnicity, comorbid illness, allocation to
active ECS, type and duration of heparin and warfarin use,
type of DVT (unprovoked vs. secondary; anatomic extent
of DVT), and recurrent DVT during follow-up. The analy-
ses will aim to (1) identify the strength of the association
between relevant biomarkers, other relevant explanatory
variables and PTS; and (2) explore relevant interactions.
Similarly, multiple linear regression will be performed in
which the dependent variable is the severity of PTS, as
measured by the Villalta scale.
An interim analysis for efficacy will be performed when
half of the subjects have completed 2 years of follow-up.
The analysis plans call for a Lan-DeMets alpha spending
approach with an O'Brien Fleming boundary [70].
Data management
All data are collected using standardized case report
forms. Data is entered on-line at study sites using a cus-
tomized web-based data entry tool, and data quality is
maintained via use of validation checks at the time of data
entry. Data will be reviewed and cleaned by the database
coordinator on an on-going basis by initiating and follow-
ing up on queries to the sites. Data management is being
overseen by TrialStat® (Ottawa, Canada). Analysis of the
cleaned database will be carried out at the coordinating
center under the supervision of study principal investiga-
tors.
Trial committees
The Steering Committee is chaired by the study principal
investigator and includes the trial coordinator and all SOX
Trial grant co-applicants. The Steering Committee meets
regularly and on an as-needed basis to monitor trial
progress, assess the need for changes in procedures, and
address issues that could affect the integrity or projected
timeframe of the trial. The Expert Adjudication Commit-
tee for all outcome events is comprised of two thrombosis
experts who are not co-investigators or collaborators.
Clinical details and diagnostic studies relating to sus-
pected outcome events and deaths are reviewed by the
committee, who are blinded to treatment assignment. The
Independent Data Safety and Monitoring Committee con-
sists of an experienced thrombosis physician, a biostatisti-
cian and an experienced clinical trialist. Episodes of
symptomatic recurrent venous thromboembolism, the
post-thrombotic syndrome, and death from all causes are
reported to the Chair of the Committee on a quarterly
basis.
Ethical considerations
Each patient is provided with written information about
the trial and written informed consent is obtained prior to
study inclusion. The study protocol has been approved by
Health Canada and by the local Research Ethics Commit-
tees of the participating centres.
Discussion
In this report, we describe the protocol of a multicenter
randomized placebo controlled trial of elastic compres-
sion stockings for the prevention of post-thrombotic syn-
drome (The SOX Trial). This large, methodologically
rigorous study is evaluating the effectiveness and cost-BMC Cardiovascular Disorders 2007, 7:21 http://www.biomedcentral.com/1471-2261/7/21
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effectiveness of ECS to prevent PTS and has been designed
to provide definitive data on the role of ECS in the preven-
tion of PTS. As such, our results will impact directly on the
care of patients with DVT. This will also be the first study
to prospectively evaluate the predictive role of biomarkers
that are reflective of putative underlying pathophysiolog-
ical mechanisms in the development of clinical PTS (Bio-
SOX biomarker substudy). Our findings will increase
understanding of PTS and could result in the develop-
ment of novel therapies aimed at candidate biomarkers.
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